Biologics for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Feb 17, 2017

In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.

Plaque psoriasis typically does not respond to topical medications used for psoriasis, but biologics, like brodalumab which was approved by the FDA this week, have generally performed well in clinical trials. In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.Â

(Top left Â©JacekDudzinski/Shutterstock.com; Top right Â©Molekuulbe/Shutterstock.com; Bottom left Â©IgorZakowski/Shutterstock.com; Bottom right Â©FreeBirdPhotos/Shutterstock.com)

Yun Tong, MD; Andrew J. Peranteau, MD; Zeena Nawas, MD; Stephen K. Tyring, MD, PhD. "A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis," Skin Therapy Letter. January 2017. http://www.skintherapyletter.com/2017/22.1/1.htmlFDA approves new psoriasis drug. FDA news release. Feb. 15, 2017.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733136/

http://onlinelibrary.wiley.com/doi/10.1002/acr.23092/full

http://onlinelibrary.wiley.com/doi/10.1111/bjd.15381/abstract

http://www.nejm.org/doi/full/10.1056/NEJMoa1412679#t=article

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781&lng=en&nrm=iso&tlng=en

https://www.ncbi.nlm.nih.gov/books/NBK409648/https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0090652/

https://www.ncbi.nlm.nih.gov/pubmed/26273164